Drug shortage
Azacitidine Injection · Bristol Myers Squibb Co.
FDA drug shortage · Current · updated Oct 2, 2026
Key facts
| Generic name | Azacitidine Injection |
|---|---|
| Company | Bristol Myers Squibb Co. |
| Presentation | Vidaza, Injection, 100 mg (NDC 59572-102-01) |
| Dosage form | Injection |
| Status | Current |
| Therapeutic category | Oncology |
| Package NDCs | 59572-102-01 |
| First posted | Dec 18, 2020 |
| Last updated | Oct 2, 2026 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: